UK markets closed

Amgen Inc. (AMGN.SN)

Santiago - Santiago Delayed price. Currency in USD
Add to watchlist
249.25-5.91 (-2.32%)
As of 10:31AM CLT. Market open.
Full screen
Previous close255.16
Open0.00
Bid0.00 x N/A
Ask0.00 x N/A
Day's range249.25 - 249.25
52-week range249.25 - 255.16
Volume0
Avg. volume0
Market cap133.692B
Beta (5Y monthly)0.60
PE ratio (TTM)24.61
EPS (TTM)10.13
Earnings date02 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend date16 May 2024
1y target estN/A
  • PR Newswire

    AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024

    Amgen (NASDAQ:AMGN) today announced the presentation of new respiratory data at the American Thoracic Society (ATS) 2024 International Conference taking place May 12-22 in San Diego. Thirteen abstracts supporting two approved medicines and one investigational treatment will be presented.

  • PR Newswire

    AMGEN ANNOUNCES WEBCAST OF 2024 FIRST QUARTER FINANCIAL RESULTS

    Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2024 financial results on Thursday, May 2, 2024, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.

  • PR Newswire

    AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY

    Amgen (NASDAQ:AMGN) today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R), for the treatment of moderate to severe Thyroid Eye Disease (TED) in adults. TED is a serious, progressive, debilitating and potentially vision-threatening autoimmune disease that can cause proptosis (eye bulging), diplopia